Provided by Tiger Fintech (Singapore) Pte. Ltd.

Blueprint Medicines

89.58
-0.2600-0.29%
Post-market: 89.580.00000.00%16:23 EDT
Volume:669.70K
Turnover:59.83M
Market Cap:5.72B
PE:-83.93
High:90.84
Open:90.44
Low:88.00
Close:89.84
Loading ...

Blueprint Medicines Corp (BPMC) Q4 2024 Earnings Call Highlights: Record Growth and Strategic ...

GuruFocus.com
·
14 Feb

Q4 2024 Blueprint Medicines Corp Earnings Call

Thomson Reuters StreetEvents
·
14 Feb

Blueprint Medicines: Positive Earnings Call Highlights Growth

TIPRANKS
·
14 Feb

Strong Market Position and Growth Potential Drive Buy Rating for Blueprint Medicines

TIPRANKS
·
14 Feb

Blueprint Medicines should be bought on any weakness, says Stifel

TIPRANKS
·
14 Feb

Optimistic Growth Potential and Market Expansion Justify Buy Recommendation for Blueprint Medicines

TIPRANKS
·
14 Feb

Blueprint Medicines selloff to be short-lived, says Oppenheimer

TIPRANKS
·
14 Feb

Wedbush Adjusts Price Target on Blueprint Medicines to $128 From $124, Maintains Outperform Rating

MT Newswires Live
·
13 Feb

Blueprint Medicines Corp reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
13 Feb

Stock Track | Blueprint Medicines Plummets 8.27% as Q4 Earnings Miss Overshadows Revenue Beat

Stock Track
·
13 Feb

Blueprint Medicines Price Target Maintained With a $133.00/Share by Needham

Dow Jones
·
13 Feb

Blueprint Medicines (BPMC) Reports Q4 Loss, Misses Revenue Estimates

Zacks
·
13 Feb

Blueprint Medicines Q4 Loss Narrows, Revenue Rises

MT Newswires Live
·
13 Feb

Earnings Flash (BPMC) Blueprint Medicines Posts Q4 Net Loss $-0.79 a Share, vs. FactSet Est of $-0.67 Loss

MT Newswires Live
·
13 Feb

Blueprint Medicines: Q4 Earnings Snapshot

Associated Press Finance
·
13 Feb

Blueprint Medicines reports Q4 EPS (79c), consensus (71c)

TIPRANKS
·
13 Feb